Latest News
Email Alerts
Sign up today and receive company updates straight to your inbox.

Company Overview
Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 37 patents granted and many patents pending worldwide.
IR Contacts
Headquarters
Canadian Operations
#100-740 McCurdy RoadKelowna, BC V1X 2P7
US Operations
2226 W. Northern AvenuePhoenix, AZ 85021
Investor Relations
IR contact
T: 250-765-6424 ext. 202
IR@lexariabioscience.com
Transfer Agent
Computershare Investor Services Inc.
T: 800-564-6253
https://www.computershare.com
Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.